Highest-materiality recent filing
Accendra Health receives NYSE notice over sub-$1 average share price, plans to cure
NYSE notified Accendra on Oct. 6, 2026 that ACH's average closing price was below $1.00 over 30 consecutive trading days.
Kenneth Gardner-Smith was named President and CEO, with a mutually agreed start date of October 5, 2026; Edward A. Pesicka remains CEO until then.
Accendra Health names Kenneth Gardner-Smith as next CEO; Scott Lloyd as Chief Commercial Officer
Gardner-Smith, Board member since Mar 2022, to assume CEO early Q4 2026; succeeds retiring Edward Pesicka.
Company will not implement at-the-market equity program; no impact on results or published guidance.
Accendra Health Q2 revenue down 10%, adjusted loss; CEO Pesicka to retire by end of 2026
Q2 net revenue $613.2M, down 10% YoY from $681.9M; GAAP EPS -$1.16 vs -$1.09.
Accendra Health CEO Ed Pesicka to retire by end of 2026; board starts successor search
CEO Edward A. Pesicka to retire by end of 2026; will also step down from board.
Accendra Health closes exchange offers: 99.9% of 2029 notes and 99.2% of 2030 notes tendered
Tendered $478.3M of 2029 notes (99.9%) and $548.0M of 2030 notes (99.2%).
Accendra Health exchanges nearly all outstanding notes for new secured notes at 9%-9.75% rates
Approximately 99.9% of 2029 Notes ($478.3M) and 99.2% of 2030 Notes ($547.9M) tendered and accepted early.
Accendra Health launches exchange offer for 4.5%/6.625% notes; new 9%/9.75% secured notes
Offer to exchange $478.7M of 4.500% 2029 notes and $552.2M of 6.625% 2030 notes for secured notes.
Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization
Q1 revenue $627.8M (down 6.8% YoY); GAAP loss from cont. ops $6.5M vs $3.8M loss prior year.
New $326.25M 9.000% Senior Secured First Lien Notes due 2032 and $300M revolver due 2030.
Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale
Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).
Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B
Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.
Sale closed for $375M cash, plus 5% retained equity and preserved tax attributes >$150M.
Owens & Minor to rename as Accendra Health; ticker changes to ACH on Jan 2, 2026
Name change to Accendra Health, Inc. effective Dec 31, 2025; NYSE ticker becomes "ACH" on Jan 2, 2026.
Owens & Minor to sell Products & Healthcare segment; Q3 adjusted EPS $0.25
Signed definitive agreement to sell Products & Healthcare Services segment, pivoting to pure-play home-based care.
Owens & Minor sells P&HS segment to Platinum Equity for $375M cash + retained equity
Cash payment of $375 million at closing, subject to customary adjustments for working capital, net debt, and expenses.
Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.
Owens & Minor to redeem $1B in 10% notes due 2030 after Rotech merger termination
Merger agreement to acquire Rotech terminated effective June 5, 2025.
Owens & Minor terminates $80M Rotech acquisition; will redeem $1B notes
Mutual termination of merger agreement; OMI pays $80M termination fee to Rotech.
Owens & Minor Q1 adj EPS $0.23, revenue $2.63B; reaffirms FY guide, active on P&HS sale
Adjusted EPS $0.23 vs $0.19 YoY; GAAP net loss $(0.32) per share vs $(0.29).
Owens & Minor closes $1B 10% senior secured notes offering to fund Rotech acquisition
$1,000,000,000 aggregate principal of 10.000% senior secured notes due 2030 issued.
Owens & Minor upsizes and prices $1B of 10.000% senior secured notes due 2030
Upsized to $1B aggregate principal at 10.000% interest, maturing April 15, 2030.
Owens & Minor launches $600M senior secured notes offering to finance Rotech acquisition
Launched $600M senior secured notes due 2030 in a private placement to QIBs and non-U.S. persons.
Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment
Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).
Q4 prelim rev $2.67-2.70B; net loss $(288-311)M; adj EBITDA $135-140M; adj EPS $0.52-0.55.
Owens & Minor Q3 revenue up 5% to $2.7B; GAAP net loss $0.17/shr; adj EPS $0.42; debt cut $198M
Consolidated revenue of $2.7B (+5% YoY); GAAP net loss $(13M) or $(0.17)/share.
Owens & Minor receives FTC Second Request for Rotech acquisition; closing expected H1 2025
Company and Rotech received FTC Second Request on October 11, 2024, extending HSR Act waiting period.
Owens & Minor Q2 revenue up 4% to $2.7B; adjusted EPS doubles to $0.36; agrees to acquire Rotech
Revenue $2.67B (+4% YoY); GAAP net loss $32M ($0.42 loss per share) vs. $28M loss last year.
Owens & Minor calls all $171.3M of 4.375% Senior Notes due 2024 for redemption
Full redemption of 4.375% Senior Notes due 2024 on September 16, 2024 at 100% of principal plus accrued interest.
Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.
Owens & Minor to buy Rotech for $1.36B cash; expects ~$0.15 EPS accretion in second year
Purchase price $1.36B cash; net $1.32B after ~$40M tax benefits; ~6.3x LTM EBITDA ex-synergies.
Owens & Minor CFO Bruni resigns at company's request; interim CFO Leon appointed
Alexander J. Bruni resigned as EVP & CFO effective June 21, 2024, will remain until Sep 5, 2024 for transition.
Owens & Minor Q1 adj EPS $0.19 (4x YoY); revenue $2.61B up 4%
Adj EPS $0.19 vs $0.05 YoY; GAAP net loss per share $(0.29) vs $(0.32).
Mr. Pesicka will remain in the role of President and CEO until Mr. Gardner-Smith assumes the role, at which point Mr. Pesicka will also retire from the Board of Directors, as previously announced.
He will succeed Edward A. Pesicka, who previously announced his intent to retire in August.
On September 17, 2026, Accendra Health, Inc. (the “Company” or “Accendra Health”) announced that it named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer.
On August 10, 2026, Accendra Health, Inc. (the “Company”) announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the “Board”) of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed.
On September 23, 2024, Owens & Minor, Inc. (the “Company”) announced that Jonathan A. Leon, age 58, has been appointed Executive Vice President, Chief Financial Officer of the Company, effective September 23, 2024.
Alexander J. Bruni, the Company’s Executive Vice President & Chief Financial Officer, has, at the request of the Company, resigned from his position as an officer of the Company, effective June 21, 2024.
Jonathan A. Leon, the Company’s Senior Vice President, Corporate Treasurer, has been appointed as interim Chief Financial Officer effective June 21, 2024.
On May 24, 2024, Owens & Minor, Inc. (the Company) named Jennifer Stone (53) Executive Vice President & Chief Human Resources Officer of the Company effective June 3, 2024.
On May 9, 2024 Owens & Minor, Inc. (the Company) named Snehashish Sarkar (49) Executive Vice President & Chief Information Officer of the Company.
On April 16, 2024, Dan J. Starck, Executive Vice President, Business Excellence of Owens & Minor, Inc. (the “Company”), informed the Company that he was retiring from his position at the Company, effective May 17, 2024.
On December 11, 2023, Tammy L. Gomez, Executive Vice President and Chief Human Resources Officer of Owens & Minor, Inc. (the “Company”), informed the Company that she was resigning from her position at the Company, effective December 15, 2023, to accept a position with a large industrial conglomerate.
The Company has named Heath H. Galloway (46) as Executive Vice President, General Counsel and Corporate Secretary effective upon Mr. Pace’s departure.
Max materiality 0.90 · Median 0.68 · Most common event earnings